No black box warning on record for Complera

As of the latest FDA labeling reviewed, Complera (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Complera medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Skin and Hypersensitivity Reactions: Severe skin and hypersensitivity reactions have been reported during postmarketing experience, including cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Immediately discontinue treatment if hypersensitivity or rash with systemic symptoms or elevations in hepatic serum biochemistries develops and closely monitor

No black box warning on record for Complera

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Skin and Hypersensitivity Reactions: Severe skin and hypersensitivity reactions have been reported during postmarketing experience, including cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Immediately discontinue treatment if hypersensitivity or rash with systemic symptoms or elevations in hepatic serum biochemistries develops and closely monitor

Complera Black Box Warning

No black box warning on record for Complera

Other warnings & precautions

Complera Black Box Warning

No black box warning on record for Complera

Other warnings & precautions